CRMD Logo

CorMedix Inc (CRMD) Stock Forecast & Price Prediction

Live CRMD Stock Price & Analysis

Home โ€บ Stocks โ€บ United States | NASDAQ | Healthcare | Biotechnology

$10.48

+0.04 (0.38%)

12 Month Price Forecast For CRMD

$10.48
Current Price
$635.90M
Market Cap
5 Ratings
Buy 5
Hold 0
Sell 0
Wall St Analyst Ratings

Distance to CRMD Price Forecasts

+81.3%
To High Target of $19.00
+62.2%
To Median Target of $17.00
+14.5%
To Low Target of $12.00

CRMD Price Momentum

+3.1%
1 Week Change
-11.9%
1 Month Change
+220.5%
1 Year Change
+29.4%
Year-to-Date Change
-24.3%
From 52W High of $13.85
+245.9%
From 52W Low of $3.03

๐Ÿค” Considering CorMedix (CRMD)?

Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.

Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.

Data last updated: February 15, 2025 1:00 PM UTC

CRMD Analyst Ratings & Price Targets

Based on our analysis of 11 Wall Street analysts, CRMD has a bullish consensus with a median price target of $17.00 (ranging from $12.00 to $19.00). Currently trading at $10.48, the median forecast implies a 62.2% upside. This outlook is supported by 5 Buy, 0 Hold, and 0 Sell ratings.

The most optimistic forecast comes from Jason Butler at JMP Securities, projecting a 81.3% upside. Conversely, the most conservative target is provided by Gregory Renza at RBC Capital, suggesting a 14.5% upside.

Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.

CRMD Analyst Consensus

5
Buy
0
Hold
0
Sell

CRMD Price Target Range

Low
$12.00
Average
$17.00
High
$19.00
Current: $10.48

Latest CRMD Stock Forecasts by Analyst

These are the latest 20 analyst ratings and price targets for CRMD.

Date Firm Analyst Rating Change Price Target
Jan 22, 2025 D. Boral Capital Jason Kolbert Buy Maintains $15.00
Jan 13, 2025 D. Boral Capital Jason Kolbert Buy Initiates $15.00
Dec 19, 2024 RBC Capital Gregory Renza Outperform Maintains $12.00
Oct 31, 2024 Needham Serge Belanger Buy Maintains $18.00
Oct 22, 2024 Truist Securities Joon Lee Buy Maintains $17.00
Aug 26, 2024 Rodman & Renshaw Brandon Folkes Buy Initiates $13.00
Aug 15, 2024 Needham Serge Belanger Buy Reiterates $10.00
Aug 15, 2024 RBC Capital Gregory Renza Outperform Reiterates $9.00
Jul 25, 2024 Truist Securities Joon Lee Buy Maintains $12.00
Jun 19, 2024 Needham Serge Belanger Buy Reiterates $10.00
May 13, 2024 Needham Serge Belanger Buy Reiterates $10.00
Apr 9, 2024 Needham Serge Belanger Buy Reiterates $10.00
Apr 9, 2024 JMP Securities Jason Butler Market Outperform Reiterates $19.00
Mar 13, 2024 RBC Capital Gregory Renza Outperform Maintains $9.00
Mar 12, 2024 Needham Serge Belanger Buy Maintains $10.00
Jan 31, 2024 Truist Securities Joon Lee Buy Maintains $14.00
Nov 15, 2023 JMP Securities Jason Butler Market Outperform Reiterates $19.00
Nov 15, 2023 Needham Serge Belanger Buy Maintains $10.00
Nov 15, 2023 Truist Securities Joon Lee Buy Reiterates $18.00
Nov 15, 2023 RBC Capital Gregory Renza Outperform Maintains $10.00

Stocks Similar to CorMedix Inc

The following stocks are similar to CorMedix based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.

CorMedix Inc (CRMD) Financial Data

CorMedix Inc has a market capitalization of $635.90M with a P/E ratio of -11.5x. The company generates $12.26M in trailing twelve-month revenue with a 0.0% profit margin.

Revenue growth is +1,321.1% quarter-over-quarter, while maintaining an operating margin of -28.7% and return on equity of -65.0%.

Valuation Metrics

Market Cap $635.90M
Enterprise Value $590.42M
P/E Ratio -11.5x
PEG Ratio 21.8x
Price/Sales 51.9x

Growth & Margins

Revenue Growth (YoY) +1,321.1%
Gross Margin +94.0%
Operating Margin -28.7%
Net Margin 0.0%
EPS Growth N/A

Financial Health

Cash/Price Ratio +7.2%
Current Ratio 4.0x
Debt/Equity 0.9x
ROE -65.0%
ROA -37.7%

๐Ÿ”ฅ Want More High-Potential Stock Ideas?

Join 5,000+ investors getting our research on stocks with massive upside potential.

CorMedix Inc logo

CorMedix Inc (CRMD) Company Overview

About CorMedix Inc

What They Do

Develops products for infectious disease treatment.

Business Model

CorMedix Inc. generates revenue through the development and commercialization of therapeutic products aimed at preventing and treating infectious and inflammatory diseases. Their primary product candidate, DefenCath, is designed to minimize catheter-related bloodstream infections, targeting a significant healthcare market, particularly among patients with kidney failure.

Additional Information

Founded in 2006 and headquartered in Berkeley Heights, New Jersey, CorMedix was previously known as Picton Holding Company, Inc. The company has a focused strategy on addressing critical health issues in the United States, which may appeal to investors looking for opportunities in the biopharmaceutical sector.

Company Information

Sector

Healthcare

Industry

Biotechnology

Employees

82

CEO

Mr. Joseph Todisco MBA

Country

United States

IPO Year

2010

CorMedix Inc (CRMD) Latest News & Analysis

CRMD stock latest news image
Quick Summary

CorMedix Inc. reports Q4 2024 unaudited net revenue of approximately $31 million and FY 2024 net revenue of about $43 million, with Q4 adjusted EBITDA expected to exceed $12 million.

Why It Matters

CorMedix's preliminary revenue figures indicate strong performance, with Q4 revenue of $31 million and anticipated adjusted EBITDA over $12 million, signaling potential growth and financial health.

Source: GlobeNewsWire
Market Sentiment: Neutral
CRMD stock latest news image
Quick Summary

CRMD reported $31 million in preliminary Q4 sales from its sole product, exceeding its prior guidance of achieving break-even by 2024.

Why It Matters

CRMD's Q4 sales of $31 million indicate strong demand and growth potential, exceeding guidance, which could enhance investor confidence and drive stock performance.

Source: Zacks Investment Research
Market Sentiment: Positive
CRMD stock latest news image
Quick Summary

CorMedix (CRMD) and ResMed (RMD) have exhibited performance metrics that can be compared to their respective sectors year-to-date.

Why It Matters

Performance comparisons indicate how well CorMedix and ResMed are faring against their peers, influencing investor sentiment and potential investment decisions in the healthcare sector.

Source: Zacks Investment Research
Market Sentiment: Positive
CRMD stock latest news image
Quick Summary

CorMedix Inc. (Nasdaq: CRMD) will be added to the Nasdaq Biotechnology Index (NBI) effective December 23, 2024, prior to market open.

Why It Matters

CorMedix's inclusion in the Nasdaq Biotechnology Index can enhance its visibility, attract institutional investors, and potentially boost its stock price due to increased demand.

Source: GlobeNewsWire
Market Sentiment: Neutral
CRMD stock latest news image
Quick Summary

CorMedix Inc. (Nasdaq: CRMD) notes new CMS policy changes enhancing access to innovative therapies for Medicare patients with End Stage Renal Disease and on dialysis.

Why It Matters

Policy changes by CMS could enhance market opportunities for CorMedix, potentially increasing revenue from their therapeutic products for hemodialysis patients.

Source: GlobeNewsWire
Market Sentiment: Neutral
CRMD stock latest news image
Quick Summary

CorMedix (CRMD) has been upgraded to Zacks Rank #1 (Strong Buy), indicating increased optimism about its earnings prospects, potentially boosting the stock price.

Why It Matters

CorMedix's upgrade to a Zacks Rank #1 signals strong earnings potential, likely boosting investor confidence and driving the stock price up in the near term.

Source: Zacks Investment Research
Market Sentiment: Positive

Frequently Asked Questions About CRMD Stock

What is CorMedix Inc's (CRMD) stock forecast for 2025?

Based on our analysis of 11 Wall Street analysts, CorMedix Inc (CRMD) has a median price target of $17.00. The highest price target is $19.00 and the lowest is $12.00.

Is CRMD stock a good investment in 2025?

According to current analyst ratings, CRMD has 5 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $10.48. Always conduct your own research and consider your investment goals before making investment decisions.

What is the price prediction for CRMD stock?

Wall Street analysts predict CRMD stock could reach $17.00 in the next 12 months. This represents a 62.2% increase from the current price of $10.48. Please note that this is a projection by Wall Street analysts and not a guarantee.

What is CorMedix Inc's business model?

CorMedix Inc. generates revenue through the development and commercialization of therapeutic products aimed at preventing and treating infectious and inflammatory diseases. Their primary product candidate, DefenCath, is designed to minimize catheter-related bloodstream infections, targeting a significant healthcare market, particularly among patients with kidney failure.

What is the highest forecasted price for CRMD CorMedix Inc?

The highest price target for CRMD is $19.00 from Jason Butler at JMP Securities, which represents a 81.3% increase from the current price of $10.48.

What is the lowest forecasted price for CRMD CorMedix Inc?

The lowest price target for CRMD is $12.00 from Gregory Renza at RBC Capital, which represents a 14.5% increase from the current price of $10.48.

What is the overall CRMD consensus from analysts for CorMedix Inc?

The overall analyst consensus for CRMD is bullish. Out of 11 Wall Street analysts, 5 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $17.00.

How accurate are CRMD stock price projections?

Stock price projections, including those for CorMedix Inc, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.